Hims Stock Is in Freefall — But Is the Company Actually Dying or Just Changing?

A company experiences a certain kind of tension when the regulatory landscape changes. The carefully worded filings, the analyst calls, and the CEO’s constant insistence—perhaps a bit too firmly—that everything will be alright are all signs of it. That’s about where Hims & Hers Health is at the moment—between audacious ambition and a truly challenging reckoning, with its stock price speaking for itself.

When Hims & Hers first launched in 2017, their pitch was surprisingly straightforward: make it easier for men to receive treatment for conditions they were too ashamed to discuss in person with a doctor. medications for erectile dysfunction. shampoos for hair loss. A package reaching your door, a consultation conducted over the phone. Although it wasn’t glamorous, it was effective.

The company had already added a women’s health brand and mental health services by the time it went public through a SPAC merger in January 2021 and started trading on the New York Stock Exchange. Back then, the growth seemed almost effortless.

However, things became more complicated in the weight-loss chapter. Hims declared in 2024 that it would expand its product line to include compounded GLP-1 injections, which are essentially less expensive pharmacy-mixed versions of medications like Ozempic and Wegovy. It was clearly appealing. Branded semaglutide medications were costly and frequently difficult to obtain. Hims made two promises that are highly relevant to American healthcare: availability and affordability.

It might have underestimated the ensuing legal and regulatory conflict. Under US law, compounders are allowed to create customized versions of medications, but mass-producing them is a different story. Hims’s strategy was not viewed as innovative healthcare access by Novo Nordisk, the Danish pharmaceutical behemoth behind Wegovy and Ozempic. They filed a lawsuit because they believed it to be patent infringement.

The lawsuit was unsuccessful. At the beginning of 2026, Hims’ stock fell by about 48%, a sharp decline that caused even hopeful investors to hesitate. By late February, shares were trading at about $14.52, while just weeks earlier, analyst price targets had been above $29. After a quarterly earnings call, four analysts lowered their targets, bringing the mean down to $20.70. It’s the kind of figure that, when you consider how quickly the slide occurred, feels significant even though it doesn’t appear disastrous on paper.

CEO Andrew Dudum has maintained his composure in public, almost on purpose. He claimed that even in a “draconian scenario” in which compounded GLP-1s are unavailable, the company can continue to operate its weight-loss business. He might be correct. Additionally, a CEO might say precisely that when pharmaceutical companies and regulatory bodies are circling.

It was no small matter that the FDA referred Hims to the Department of Justice regarding its proposed $49 Wegovy medication. Hims swiftly changed its direction, but the reputational harm and the ongoing SEC investigation that the business revealed in February add a degree of uncertainty that is difficult to overcome by revenue projections.

Additionally, the business is managing a costly expansion that is taking place at the worst possible moment. It purchased the UK-based digital health platform ZAVA last year. Then, in February 2026, it announced the $1.6 billion purchase of Eucalyptus Health, an Australian business that operates brands like Juniper and Pilot. Both actions are strategically sound in the long run because they expand Hims’s product line in markets where branded GLP-1s, not compounded ones, are the norm and diversify away from the U.S. regulatory environment.

However, it takes time, money, and management focus to integrate global businesses. International markets have higher operating costs, but CFO Yemi Okupe acknowledged that the burden will lessen as the footprint expands. It’s really unclear if investors are prepared to wait that long.

It seems like Hims fell into a trap of its own making as you watch all of this. In 2025, the compounded GLP-1 business generated 59% revenue growth and was very profitable. Retraction from that, even in part, creates a void that will be difficult to swiftly fill through foreign acquisitions and new product lines. In 2026, the company anticipates a revenue growth of more than 15%. In isolation, that figure isn’t too bad, but when compared to last year’s results, it appears to be a major slowdown, and the market is pricing in the disappointment.

According to Morningstar analyst Kadyn Kim, there are a lot of unanswered questions. Regulatory ambiguity, litigation, and expansion expenses don’t settle on a timely basis. Semaglutide may be added to the FDA’s list of compounds to avoid. The SEC’s investigation might turn up nothing noteworthy, or it might turn up more. It’s possible that the Novo lawsuit will continue for another year or longer. While none of these results are certain, they are also not impossible.

Genuine infrastructure is what Hims has going for it—possibly more than investors are currently acknowledging. In a field where trust is difficult to gain, it established a genuine telehealth platform, a recognizable brand, and a devoted clientele. Treatments for hair loss, sexual health, and mental health issues are not going away.

There is a version of this story where Hims stock appears significantly undervalued at current prices if the company can integrate its new international assets and weather the regulatory storm without losing operational discipline. All it takes to believe that Andrew Dudum’s confidence is based on something other than necessity is to accept that version. That belief is being tested for the time being.